Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04344795
Title Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Tempest Therapeutics

colorectal cancer

Advanced Solid Tumor

urinary bladder cancer

triple-receptor negative breast cancer

head and neck squamous cell carcinoma

stomach cancer



Pembrolizumab + TPST-1495

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.